

February 08, 2018

TAKE/BSE/2017-18

The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai - 400001

TAKE/NSE/2017-18

The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400051

Dear Sir/Madam,

Sub: Press Release

Ref: NSE Scrip Code: 523890 & BSE Scrip Code: TAKE

We are pleased to enclose a press release for your reference and record.

Kindly take note of the same.

Thanking you.

Yours sincerely,
For TAKE Solutions Limited



Avaneesh Singh
Company Secretary



Encl: As above.

TAKE Solutions announces Preferential Allotment of INR 250 crores

Sustains growth momentum with Q3 FY18 profits of INR 411 Mn; Revenue saw a growth of 18.9% in INR Y-o-Y

| Figures in INR million unless mentioned | Q3 FY18 | Q3 FY17 | Y-o-Y change (%) |
|---|---------|---------|------------------|
| Revenue | 4,080 | 3,431 | 18.9% |
| EBITDA | 798 | 693 | 15.2% |
| PATMI | 411 | 370 | 11.0% |
| Diluted EPS | 3.13 | 2.81 | 11.4% |

Chennai, February 8 2018: TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a globally recognized domain intensive services provider in Life Sciences, today announced its financial results for Q3 FY18. The Company carried forward the momentum witnessed in Q2 FY18, reporting strong Q3 revenue and profit figures of INR 4,080 Mn and INR 411 Mn.

Srinivasan H R, Vice Chairman and Managing Director, TAKE Solutions said, “This quarter has witnessed strong business growth as can be seen in the financial results. In response to the emerging growth possibilities we are delighted to announce a preferential allotment of INR 250 crores to the promoters. The funds raised through this preferential issue will be used to capitalize on our opportunities and scale our business in the Clinical and Regulatory spaces inorganically through strategic acquisitions in North America and Europe markets.”

Highlights of the quarter:

- EBITDA grew 15.2% in INR Y-o-Y
- Revenue saw a growth 18.9% in INR Y-o-Y.
- Life Sciences revenue grew by 25.4 % (INR) Y-o-Y.
- Customer base of small and medium pharma for PharmaReady software has crossed 150 and climbing steadily
- Scales BA/BE business with an 80 bedded Clinical Pharmacology Unit which will be ready to commence operations soon
- Aligns all capabilities to digitize research and development of life sciences

About TAKE Solutions Limited

TAKE Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management.

In the fast-growing Life Sciences space, TAKE offers clients a unique combination of a full-service CRO backed by industry insights and technology expertise. Our range of services span





from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through our proprietary industry networks. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers outcomes for clients, including 9 of the top 10 global pharmaceutical companies.

In Supply Chain Management, TAKE focuses on high-margin niches in engineering, mobility and collaboration. Our IP-led approach enables our clients to automate supply chain processes, track, trace & control at item level, extend mobility, mandate supplier compliance, and streamline material & shipment movement, and thus optimize their processes.

With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange. Led by a team of industry stalwarts and domain experts, TAKE has been growing steadily with FY17 revenues touching INR 13,520 Mn, a 29% increase year-on-year.

For more details, please visit www.takesolutions.com

For media information:

Samhita Suresh, TAKE Solutions, +91 44 66110700, samhita.suresh@takesolutions.com
Jayeeta Chowdhury, 20:20 MSL, +91 9962750769, jayeeta.chowdhury@2020msl.com

